Navigation Links
New Drug Shows Promise for Myeloma Patients
Date:5/9/2012

By Serena Gordon
HealthDay Reporter

WEDNESDAY, May 9 (HealthDay News) -- Three new studies confirm that the drug lenalidomide can significantly lengthen the time that people with multiple myeloma experience no worsening of their disease, either after having a stem cell transplant or getting chemotherapy.

However, what isn't clear from the studies is whether or not the improved "progression-free" survival time will translate to a longer overall survival.

"These are very promising, early studies," said the author of an accompanying editorial, Dr. Ashraf Badros, a professor in the department of medicine at the University of Maryland School of Medicine, in Baltimore. "I think these studies will generate a lot of discussion."

Potential areas of debate, he said, include whether or not progression-free survival is enough if there isn't an overall survival benefit. He said that progression-free survival may well justify this treatment if quality of life is significantly improved. However, none of the studies looked at quality-of-life measures. Another important factor is cost; this drug is estimated to cost about $163,381 a year to treat one patient, according to Badros' editorial.

The studies and the editorial are published in the May 10 issue of the New England Journal of Medicine.

Multiple myeloma is a cancer that affects plasma cells in the blood. Each year, about 22,000 Americans are diagnosed with multiple myeloma, according to the American Cancer Society. The current five-year survival rate for multiple myeloma is only 40 percent. However, recent advances will likely increase the survival rate for people who are diagnosed going forward, according to the cancer society.

Lenalidomide (Revlimid) alters the immune system response, and has direct toxic effects on tumors, according to background information in one of the studies.

In younger people, the standard treatment is generally a stem cell transplant to replace the many of the cancerous plasma cells. However, many older patients are ineligible for this treatment.

The first study looked at lenalidomide treatment in people who weren't candidates for stem cell transplants, and it included just over 450 people over age 65 who had recently been diagnosed with multiple myeloma. One group received initial chemotherapy that included lenalidomide that was also followed by maintenance therapy with lenalidomide, while the second group just received the initial chemotherapy including lenalidomide. The final group received standard chemotherapy without lenalidomide.

After an average follow-up period of 30 months, the researchers found that the first group had an average progression-free survival of 31 months compared with just 14 months for the second group and only 13 months for the final group. This study wasn't designed to assess overall survival.

"This approach is approximately doubling the remission duration of old therapies from 15 to 30 months," said study author Dr. Antonio Palumbo, from the department of hematology at the University of Torino in Italy.

Palumbo said that cost always has to be considered in treatments. He said there are some cost savings associated with lenalidomide because it's an oral medication, not one that has to be given intravenously. In addition, if it prevents complications, such as bone fractures, it may help prevent hospitalization costs and disability.

The second study, conducted by researchers from Roswell Park Institute in New York, included 468 people younger than 71 years old who were undergoing stem cell transplants. Beginning 100 days after their transplants, half the group was given daily lenalidomide and the other half received placebo. Once the disease progressed, study participants were told which treatment they were receiving, and if they were on placebo, they were allowed to start taking lenalidomide.

At the time results were unblinded, just 20 percent of those on lenalidomide had disease progression compared with 44 percent of those on placebo.

The third study, reported by French researchers, also looked at lenalidomide maintenance therapy in people who'd had a stem cell transplant. This study included 614 people younger than 65. The group taking lenalidomide had an average progression-free survival of 41 months compared to 23 months with placebo. Four years after the study began, the average overall survival was similar in both groups, according to the study.

The most significant and concerning side effect was an increased risk of a second cancer. In all three studies, the rate of second cancers was more than doubled in people taking lenalidomide. Low white blood cell counts were also more commonly associated with lenalidomide therapy.

Badros said that all cancer treatments have side effects, and that for the most part, lenalidomide didn't appear to have any unexpected effects, except for the increased rate of second cancers. That finding, he said, warrants further study.

More information

Learn more about multiple myeloma from the American Cancer Society.

SOURCES: Ashraf Badros, M.B., Ch.B., professor, department of medicine, University of Maryland School of Medicine and University of Maryland Medical Center, Baltimore; Antonio Palumbo, M.D., department of hematology, University of Torino, Italy; May 10, 2012, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. First blinded study of venous insufficiency prevalence in MS shows promising results
2. People with anxiety disorder less able to regulate response to negative emotions, study shows
3. Poll Shows Eroding Support for Health Reform
4. Protecting patients: Study shows that Johns Hopkins flu vaccination rates twice national average
5. Compound shows promise against intractable heart failure
6. Drama or reality TV: Do medical shows depict proper first aid for seizures?
7. TV Shows Often Botch Proper Seizure Responses
8. UQ research shows canecutters disease on the rise among travelers
9. Brain Scan Shows What Beauty is Worth
10. Untreated poor vision in elderly linked to dementia, University of Michigan study shows
11. New research shows emotional impact of low sexual desire and associated distress
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Drug Shows Promise for Myeloma Patients
(Date:12/8/2016)... ... December 08, 2016 , ... The ... beginning January 1, 2017. The name change aligns the entire company with ... improving health care quality. , “We are very proud of the achievements associated ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Florida Hospital Tampa ... Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric medicine. This accreditation identifies ... few hospitals and facilities have earned this distinction. This is the second time ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... (WCRI) officially opened registration today for its 33rd Annual Issues & Research ... . , The theme of the conference is “Persistent Challenges and New Opportunities: ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported ... , “This was our first franchise-wide Quack Gives Back initiative, and ...
(Date:12/8/2016)... ... December 08, 2016 , ... ZyDoc , a New ... Conventional Data Capture Methods for Input to Electronic Health Records: A Comparative Usability ... the comparative usability study demonstrate that a dictation-based method (“NLP Entry”) using ZyDoc’s ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... IRIDEX Corporation (NASDAQ: IRIX ) today ... common stock, $0.01 par value (the "Offering" with such shares ... final terms of the Offering will depend on market and ... be no assurance as to whether or when the Offering ... net proceeds it will receive from this offering for working ...
(Date:12/8/2016)... LONDON , Dec. 8, 2016 Australia ... GlobalData,s new report, "Australia Ophthalmic Lasers Market Outlook to ... Lasers market. The report provides value, in millions of ... within market segements - Excimer Lasers, Femtosecond Lasers and ... and distribution shares data for each of these market ...
(Date:12/8/2016)... , Dec. 8, 2016 Australia ... Summary GlobalData,s new report, "Australia Glaucoma Surgery ... data on the Australia Glaucoma Surgery Devices market. ... dollars, volume (in units) and average prices (USD) ... The report also provides company shares and distribution ...
Breaking Medicine Technology: